Journal Mobile Options
Table of Contents
Vol. 213, No. 2, 2006
Issue release date: August 2006
Dermatology 2006;213:134–139
(DOI:10.1159/000093852)

Excimer Laser versus Narrow-Band UVB (311 nm) in the Treatment of Psoriasis Vulgaris

Goldinger S.M. · Dummer R. · Schmid P. · Prinz Vavricka M. · Burg G. · Läuchli S.
aDepartment of Dermatology, University of Zurich, and bHaut- und Lichtzentrum, Zurich, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The excimer laser is a new therapeutic option in the treatment of psoriasis vulgaris. Objective: The purpose of this study was to determine the response of psoriasis lesions to the 308-nm excimer laser compared to 311-nm UVB phototherapy. Methods: In this prospective right/left comparative, open, single-blinded trial, selected psoriasis plaques of 16 patients were treated with the excimer laser whereas the rest of the body was treated with UVB narrow-band phototherapy. A modified PASI score was used to evaluate the results. Results: After 12 treatments, 15 patients were evaluated. In 2 patients no difference between the two body sides was observed. In 9 patients the laser-treated lesions showed better results, whereas in 4 patients the side treated with 311-nm UVB showed more clearing. The mean reduction in PASI score was 5.6 and 4.9, respectively (difference not significant). Conclusion: The use of the 308-nm xenon chloride excimer laser is an additional effective therapeutic option for the treatment of psoriasis vulgaris.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Zanolli M: Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003;49(suppl 2):S78–S86.

    External Resources

  2. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG: Narrow-band UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broad-band UV-B. Arch Dermatol 1997;133:1514–1522.
  3. Dummer R, Ivanova K, Scheidegger EP, Burg G: Clinical and therapeutic aspects of polymorphous light eruption. Dermatology 2003;207:93–95.
  4. Carrozza P, Hausermann P, Nestle FO, Burg G, Boni R: Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis: an open pilot study. Dermatology 2000;200:35–39.
  5. Bónis B, Kemeny L, Dobozy A, Bor Z, Szabo G, Ignacz F: 308 nm UVB excimer laser for psoriasis. Lancet 1997;350:1522.
  6. Taneja A, Trehan M, Taylor CR: 308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry. Arch Dermatol 2003;139:759–764.
  7. Asawanonda P, Anderson RR, Chang Y, Taylor CR: 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 2000;136:619–624.
  8. Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL: Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002;46:900–906.
  9. Landthaler M, Ulrich H, Hohenleutner S, Wimmershoff M, Hohenleutner U: Role of laser therapy in dermatology – Clinical aspects. Dermatology 2004;208:129–134.
  10. Passeron T, Ortonne JP: The 308 nm excimer laser in dermatology. Presse Méd 2005;34:301–309.
  11. Kollner K, Wimmershoff MB, Hintz C, Landthaler M, Hohenleutner U: Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis. Br J Dermatol 2005;152:750–754.
  12. Duthie MS, Kimber I, Norval M: The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999;140:995–1009.
  13. Schon MP, Boehncke WH: Psoriasis. N Engl J Med 2005;352:1899–1912.
  14. Lebwohl M: Psoriasis. Lancet 2003;361:1197–1204.
  15. Weischer M, Blum A, Eberhard F, Rocken M, Berneburg M: No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004;84:370–374.
  16. Gerber W, Arheilger B, Ha TA, Hermann J, Ockenfels HM: Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. Br J Dermatol 2003;149:1250–1258.
  17. Nóvak Z, Bonis B, Baltas E, Ocsovszki I, Ignacz F, Dobozy A, Kemeny L: Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B 2002;67:32–38.
  18. Ozawa M, Ferenczi K, Kikuchi T, Cardinale I, Austin LM, Coven TR, Burack LH, Krueger JG: 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999;189:711–718.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50